Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups

(RTTNews) - Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced results from an analysis of real-world data pooled from four large U.S. insurance claims databases. The company reported that, among non-valvular atrial fibrillation (NVAF) patients, Eliquis (apixaban) was associated with a lower risk of stroke/SE and lower rates of major bleeding compared to warfarin for the overall population as well as for each of the selected high-risk patient sub-populations.

The company said the observational cohort analysis adds to the body of evidence for Eliquis, which notably includes the Phase 3 ARISTOTLE clinical trial in which the reduction in risk for stroke/SE, the primary efficacy endpoint for ARISTOTLE, was generally consistent for Eliquis compared with warfarin across various patient subgroups.